IPHARMA Tirzepatide is an advanced, dual-acting research compound targeting both GIP and GLP-1 receptors. This 30mg (2.4ml) peptide is provided in a convenient, pre-filled peptide pen format, specifically engineered for precision in laboratory settings. It is widely utilized in studies exploring metabolic regulation, insulin signaling, glucose homeostasis, and energy balance in controlled experimental models.
Key Research Benefits
Appetite Control: Supports the study of reduced food cravings and suppressed appetite.
Satiety Support: Helps research models promote feelings of fullness and better portion control.
Metabolic Regulation: Assists in studying blood sugar balance and the optimization of insulin signaling pathways.
Body Composition: Provides a specialized tool for investigating effective fat loss and body composition management.
Energy Balance: Designed to help researchers explore advanced pathways in systemic metabolic health and energy homeostasis.
IPHARMA Semaglutide 5mg Pre-Filled Pen
The IPHARMA Semaglutide 5mg Pre-Filled Pen is supplied in a convenient pre-filled format for easy handling and storage. Manufactured to high quality standards, this product offers secure packaging and reliable quality.
About Semaglutide
Semaglutide is a well-known peptide that has gained significant attention within the wellness community. It is commonly associated with appetite management, metabolic wellness, and weight management support. Semaglutide continues to be one of the most widely discussed peptides in the field of wellness and lifestyle support.
Product Information
• Brand: IPHARMA
• Product: Semaglutide
• Strength: 5mg
• Format: Pre-Filled Pen
• Packaging: Sealed Unit
Features
• Convenient pre-filled pen format
• Premium quality formulation
• Secure packaging
• Easy storage and handling
• Manufactured to high quality standards
Storage
Store according to the manufacturer’s recommendations. Protect from excessive heat, moisture, and direct sunlight.
UPA RETLIRA Retatrutide Pre-Filled Pen 30mg – Premium Advanced Weight Management Therapy
The UPA RETLIRA Retatrutide Pre-Filled Pen 30mg is a premium triple-agonist peptide therapy designed for advanced weight management, appetite control, and metabolic optimization. Developed and formulated by UPA, this pre-filled pen delivers 30mg of Retatrutide in a convenient once-weekly format, making it simple to integrate into structured wellness and weight-loss programs. Retatrutide targets GLP-1, GIP, and glucagon receptors, helping reduce cravings, enhance satiety, and support overall metabolic efficiency
.Properties and Mechanism of Action
UPA RETLIRA Retatrutide is a triple-agonist peptide that works through three complementary metabolic pathways:
GLP-1 receptor activation – promotes appetite suppression and improved satiety
GIP receptor activation – supports insulin sensitivity and efficient energy utilization
Glucagon receptor activation – aids fat metabolism and overall metabolic balance
This triple-receptor mechanism provides comprehensive metabolic support and optimized weight-management outcomes.
Effects and Results
When used as part of a guided weight-loss plan, UPA RETLIRA Retatrutide may help users experience:
Reduced appetite and cravings
Increased feelings of fullness and improved portion control
Enhanced fat metabolism and energy regulation
Support for healthy blood sugar levels and overall metabolic function
Results may vary depending on individual lifestyle, diet, and exercise.
How to Take
The UPA RETLIRA Retatrutide Pen is administered via subcutaneous injection, typically once weekly.
Recommended guidance includes:
Start with a low initial dose to support tolerability
Gradual dose escalation over several weeks
Maintain consistent weekly administration for best results
Possible Side Effects
Some individuals may experience mild to moderate side effects, particularly during dose escalation:
Nausea
Reduced appetite
Gastrointestinal discomfort (bloating, constipation, diarrhea)
Fatigue
Headache
Side effects are generally temporary and tend to subside as the body adjusts.
UPA TIDLIRA Tirzepatide Pre-Filled Pen 30mg – Premium Advanced Weight Management Therapy
The UPA TIDLIRA Tirzepatide Pre-Filled Pen 30mg is a premium dual-agonist peptide therapy designed for advanced weight management, appetite control, and metabolic optimization. Developed and formulated by UPA, this pre-filled pen delivers 30mg of Tirzepatide in a convenient once-weekly format, making it simple to integrate into structured wellness and weight-loss programs. Tirzepatide targets both GLP-1 and GIP receptors, helping reduce cravings, improve satiety, and enhance metabolic efficiency
.Properties and Mechanism of Action
UPA TIDLIRA Tirzepatide is a dual-agonist peptide that works by activating two key metabolic pathways:
GLP-1 receptor activation – promotes appetite suppression and improved satiety
GIP receptor activation – supports insulin sensitivity and efficient energy utilization
Supports metabolic balance – aids fat metabolism and overall metabolic function
This dual-receptor mechanism provides targeted metabolic support and enhanced weight-management benefits.
Effects and Results
When used as part of a guided weight-loss plan, UPA TIDLIRA Tirzepatide may help users experience:
Reduced appetite and cravings
Increased feelings of fullness and improved portion control
Enhanced fat metabolism and energy regulation
Support for healthy blood sugar levels and overall metabolic function
Results may vary depending on individual lifestyle, diet, and exercise.
How to Take
The UPA TIDLIRA Tirzepatide Pen is administered via subcutaneous injection, typically once weekly.
Recommended guidance includes:
Start with a low initial dose to support tolerability
Gradual dose escalation over several weeks
Maintain consistent weekly administration for best results
Possible Side Effects
Some individuals may experience mild to moderate side effects, particularly during dose escalation:
Nausea
Reduced appetite
Gastrointestinal discomfort (bloating, constipation, diarrhea)
Fatigue
Headache
Side effects are generally temporary and tend to subside as the body adjusts.
Magtidelira 33 is a next-generation injectable peptide therapy combining 3 mg of Semaglutide and 30 mg of Tersepitide (a close analogue to Tirzepatide). Designed to synergize powerful mechanisms for both metabolic regulation and weight management, this dual-agent formula addresses blood sugar control and appetite suppression in one advanced treatment.
Key Benefits
Superior Blood Sugar Control
Semaglutide (GLP-1 receptor agonist) enhances insulin release, curbs glucagon secretion, and slows gastric emptying to stabilize blood sugar levels.
Tersepitide (akin to Tirzepatide) adds dual action through both GIP and GLP-1 receptor activation, potentially offering greater improvements in glycemic control.
Potent Weight Management
Semaglutide promotes satiety and reduces appetite.
Tersepitide?s dual-action profile (GLP-1 + GIP) tends to drive higher average weight loss than GLP-1 monotherapy. Clinical trials show:
Semaglutide: ~17% average weight reduction over 68 weeks.
Tirzepatide (as proxy for Tersepitide): up to 21% weight loss over 72 weeks, depending on dose.
Metabolic and Cardiovascular Gains
Semaglutide is linked with lower cardiovascular event risk in vulnerable populations.
Tersepitide adds enhanced metabolic benefits, with trial data reporting significant improvements in obesity-related quality of life.
Convenient Weekly Dosing
Both agents feature extended half-lives that support once-weekly subcutaneous injections for consistent therapeutic levels.
Usage Guidelines
Administer via subcutaneous injection, ideally once a week on a consistent day.
Start with your healthcare provider?s recommended titration ? especially important if new to GLP-1 or dual agonists.
Incorporate a balanced, reduced-calorie diet and increased physical activity for optimal results.
Potential Side Effects
Common: gastrointestinal symptoms like nausea, vomiting, diarrhea, constipation, and decreased appetite ? typically transient and dose-related.
Other risks: possible pancreatitis, kidney function changes, and hypoglycemia, particularly when combined with other glucose-lowering agents.
Precaution: Products combining semaglutide, tirzepatide, or retatrutide may not be approved or may be marketed illegally. The FDA warns against unapproved versions labeled as ?for research only.?
Always consult your healthcare provider prior to initiation.
Why Choose Magtidelira 33?
This dual-peptide formulation merges the established benefits of Semaglutide with the enhanced metabolic potency of Tersepitide, offering a comprehensive therapeutic profile for type 2 diabetes, obesity, and metabolic syndrome. With once-weekly dosing, users can benefit from:
Enhanced appetite suppression
Improved glycemic control
Greater and more sustained weight loss
Potential added metabolic and cardiovascular support
By combining these powerful mechanisms, Magtidelira 33 may offer a more potent and balanced approach than using either agent alone.
The UPA Semaglutide 5mg Pre-Filled Pen is supplied in a convenient pre-filled format for easy handling and storage. Manufactured to high quality standards, this product offers secure packaging and reliable quality.
About Semaglutide
Semaglutide is a well-known peptide that has gained significant attention within the wellness community. It is commonly associated with appetite management, metabolic wellness, and weight management support. Semaglutide continues to be one of the most widely discussed peptides in the field of wellness and lifestyle support.
About Maglira
Maglira is a UPA product line developed to provide a convenient and reliable pre-filled pen format for Semaglutide products.
The UPA Upret 60mg Self-Mix Vial contains Retatrutide in a lyophilized powder format. Manufactured to high quality standards, this product offers secure packaging, reliable quality, and convenient storage.
About Upret
Upret is UPA’s Retatrutide formulation and has gained significant attention within the wellness community. It is commonly associated with vitality support, wellness support, active lifestyles, and overall wellbeing.
Product Information
• Brand: UPA
• Product: Upret (Retatrutide)
• Strength: 60mg
• Format: Self-Mix Lyophilized Powder Vial
• Packaging: Sealed Vial
Features
• High-purity Retatrutide formulation
• Self-mix vial format
• Premium quality formulation
• Secure packaging
• Easy storage and handling
• Manufactured to high quality standards
Storage
Store according to the manufacturer’s recommendations. Protect from excessive heat, moisture, and direct sunlight.
The UPA Upret 30mg Self-Mix Vial contains Retatrutide in a lyophilized powder format. Manufactured to high quality standards, this product offers secure packaging, reliable quality, and convenient storage.
About Upret
Upret is UPA’s Retatrutide formulation and has gained significant attention within the wellness community. It is commonly associated with vitality support, wellness support, active lifestyles, and overall wellbeing.
Product Information
• Brand: UPA
• Product: Upret (Retatrutide)
• Strength: 30mg
• Format: Self-Mix Lyophilized Powder Vial
• Packaging: Sealed Vial
Features
• High-purity Retatrutide formulation
• Self-mix vial format
• Premium quality formulation
• Secure packaging
• Easy storage and handling
• Manufactured to high quality standards
Storage
Store according to the manufacturer’s recommendations. Protect from excessive heat, moisture, and direct sunlight.
UPA Upzep 60mg (Tirzepatide) Self-Mix Vial
The UPA Upzep 30mg Self-Mix Vial contains Tirzepatide in a lyophilized powder format. Manufactured to high quality standards, this product offers secure packaging, reliable quality, and convenient storage.
About Upzep
Upzep is UPA’s Tirzepatide formulation and has gained significant attention within the wellness community. It is commonly associated with vitality support, wellness support, active lifestyles, and overall wellbeing.
Product Information
• Brand: UPA
• Product: Upzep (Tirzepatide)
• Strength: 30mg
• Format: Self-Mix Lyophilized Powder Vial
• Packaging: Sealed Vial
Features
• High-purity Tirzepatide formulation
• Self-mix vial format
• Premium quality formulation
• Secure packaging
• Easy storage and handling
• Manufactured to high quality standards
Storage
Store according to the manufacturer’s recommendations. Protect from excessive heat, moisture, and direct sunlight.
UPA Upzep 30mg (Tirzepatide) Self-Mix Vial
The UPA Upzep 30mg Self-Mix Vial contains Tirzepatide in a lyophilized powder format. Manufactured to high quality standards, this product offers secure packaging, reliable quality, and convenient storage.
About Upzep
Upzep is UPA’s Tirzepatide formulation and has gained significant attention within the wellness community. It is commonly associated with vitality support, wellness support, active lifestyles, and overall wellbeing.
Product Information
• Brand: UPA
• Product: Upzep (Tirzepatide)
• Strength: 30mg
• Format: Self-Mix Lyophilized Powder Vial
• Packaging: Sealed Vial
Features
• High-purity Tirzepatide formulation
• Self-mix vial format
• Premium quality formulation
• Secure packaging
• Easy storage and handling
• Manufactured to high quality standards
Storage
Store according to the manufacturer’s recommendations. Protect from excessive heat, moisture, and direct sunlight.